GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Viking Therapeutics Inc (LTS:0VQA) » Definitions » 14-Day RSI

Viking Therapeutics (LTS:0VQA) 14-Day RSI : 40.43 (As of Jun. 01, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Viking Therapeutics 14-Day RSI?

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.

As of today (2024-06-01), Viking Therapeutics's 14-Day RSI is 40.43.

The industry rank for Viking Therapeutics's 14-Day RSI or its related term are showing as below:

LTS:0VQA's 14-Day RSI is ranked better than
72.33% of 1565 companies
in the Biotechnology industry
Industry Median: 44.84 vs LTS:0VQA: 40.43

Competitive Comparison of Viking Therapeutics's 14-Day RSI

For the Biotechnology subindustry, Viking Therapeutics's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Viking Therapeutics's 14-Day RSI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Viking Therapeutics's 14-Day RSI distribution charts can be found below:

* The bar in red indicates where Viking Therapeutics's 14-Day RSI falls into.



Viking Therapeutics  (LTS:0VQA) 14-Day RSI Calculation

The formula for calculating RSI is:

RSI=100[ 100 / ( 1 + Average Gain / Average Loss )]

* Note that the formula uses a positive value for the average loss.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Viking Therapeutics  (LTS:0VQA) 14-Day RSI Explanation

The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.

Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.

RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.


Viking Therapeutics 14-Day RSI Related Terms

Thank you for viewing the detailed overview of Viking Therapeutics's 14-Day RSI provided by GuruFocus.com. Please click on the following links to see related term pages.


Viking Therapeutics (LTS:0VQA) Business Description

Traded in Other Exchanges
Address
9920 Pacific Heights Boulevard, Suite 350, San Diego, CA, USA, 92121
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.

Viking Therapeutics (LTS:0VQA) Headlines

No Headlines